PDUFA Dates Explained: What Every Biotech Investor Needs to Know

The Prescription Drug User Fee Act — originally enacted in 1992 and most recently reauthorized as PDUFA VII in 2022 — established a system where pharmaceutical companies pay fees to the FDA in exchange for committed review timelines. Without PDUFA, drug applications could sit in queue for years. With it, the FDA commits to specific deadlines. When a company submits a New Drug Application (NDA) or Biologics License Application (BLA), the FDA has 10 months for a standard review or 6 months for a priority review to issue a decision. The deadline is called the PDUFA date — the date by which the FDA must act. Three outcomes are possible: approval (the drug can be marketed), a Complete Response Letter (the FDA identifies deficiencies that must be addressed), or the FDA may extend its own review timeline by issuing a 3-month extension. The FDA can also act early — and frequently does for priority reviews, sometimes approving a drug weeks before the PDUFA date.

PDUFA decisions create some of the most dramatic price movements in all of public markets: Approval — For small-cap biotechs, approval of a lead program typically drives a 30-100%+ stock move, depending on how much was already priced in by the market. If the drug addresses a large market and approval was uncertain, the move can be even larger. For companies with multiple approved products, the move is more muted. Complete Response Letter (CRL) — The FDA identifies deficiencies that prevent approval. This is effectively a rejection that resets the timeline by 6-12+ months (sometimes longer if new clinical data is required). Stocks typically drop 40-80% on a CRL, as the entire near-term thesis collapses. CRLs based on manufacturing issues are generally more recoverable than those citing clinical efficacy concerns. FDA extends review — The agency requests a 3-month extension, usually to review additional data submitted late in the cycle. Stocks typically drop 10-30% on the uncertainty, though the thesis remains intact. Extensions are more common than most investors realize — they occur in roughly 15-20% of applications. The magnitude of any move depends on the market's prior probability of approval. A drug with a 90% consensus approval probability will move less on actual approval (it was priced in) but catastrophically on a CRL (it was not priced in).

PDUFA dates come from three sources: 1. FDA's own calendar — The FDA publishes a list of upcoming PDUFA dates, but it is updated irregularly and not always complete. It's a reasonable starting point but should not be your only source. 2. Company press releases — When the FDA accepts an NDA or BLA for review, the company issues a press release disclosing the PDUFA date. This is usually the most reliable source, as the company has a direct communication from the FDA. However, some companies initially only disclose a range ("second half of 2026") until the formal acceptance letter arrives. 3. Aggregators — BiotechEdge's catalyst calendar combines FDA disclosures, company press releases, and ClinicalTrials.gov data to surface upcoming PDUFA dates, Phase 3 readouts, and advisory committee meetings in a single view. The calendar is updated weekly and cross-referenced against multiple sources. Tracking PDUFA dates manually across dozens of biotech companies is time-consuming and error-prone. The value of an aggregated calendar is not just convenience — it's the ability to see all upcoming catalysts in one view and identify patterns (multiple PDUFAs in the same therapeutic area, for example).

Specialist biotech hedge funds do not buy stocks the week before a PDUFA and hope for the best. Their positioning cycle begins months earlier: Phase 1: Clinical analysis — The fund's biotech analysts review the clinical data package in detail: efficacy endpoints, safety signals, comparator performance, subgroup analyses. Many specialist funds employ former FDA reviewers or clinical researchers who can assess the strength of the submission. Phase 2: Regulatory assessment — Is the FDA likely to convene an advisory committee? Has the agency issued a Refuse to File letter? Are there outstanding manufacturing questions? Each of these factors affects the probability and timing of approval. Phase 3: Position building — High-conviction funds build positions months before the PDUFA, not days. This is visible in 13F data: a fund that initiates a new position in Q1 ahead of a Q3 PDUFA is expressing a considered view, not gambling. When multiple specialist funds build positions in the same stock ahead of the same catalyst, the signal is especially strong. The Verdad white paper data shows that stocks most heavily owned by specialist biotech funds outperform significantly — and PDUFA dates are a primary driver. The funds' clinical expertise translates into better probability-weighting of binary outcomes.

For some applications, the FDA convenes an advisory committee (AdCom) — a panel of outside medical experts who review the clinical data and vote on whether the drug should be approved. AdCom votes are non-binding but highly influential: the FDA follows the committee's recommendation roughly 75-80% of the time. An AdCom creates a "mini-catalyst" weeks or months before the PDUFA itself. A strongly positive vote (e.g., 12-1 in favor) can move a stock 20-40% and substantially de-risk the subsequent PDUFA decision. A negative vote (e.g., 4-8 against) is often devastating, typically driving a 30-50% decline. Not all NDAs receive an AdCom. The FDA is more likely to convene one when the drug involves a novel mechanism of action, when the safety profile raises questions, when the clinical data is borderline, or when the drug addresses a disease with existing treatments and the benefit-risk comparison is nuanced. For investors, an AdCom date is just as important to track as the PDUFA date. BiotechEdge's catalyst calendar includes advisory committee meetings alongside PDUFA dates and Phase 3 readouts.

The highest-conviction biotech investment setup is a company approaching a PDUFA where multiple independent signals align: 1. Specialist funds are adding positions — visible in 13F data on BiotechEdge. When 3+ dedicated biotech funds hold the stock going into a PDUFA, it reflects independent clinical analysis from teams with deep FDA experience. 2. Insiders are buying — visible in Form 4 data. Corporate insiders purchasing shares ahead of their own PDUFA date is a particularly informative signal, given the information asymmetry. 3. The company is funded through the PDUFA — visible on BiotechEdge company pages. A company with 2 quarters of cash and a PDUFA in 3 quarters will likely need to raise money first — diluting existing shareholders regardless of the FDA outcome. 4. Short interest is low or declining — visible in FINRA data. Low short interest means the market is not actively betting against the stock, reducing the risk of a crowded trade. This composite signal framework — fund conviction, insider alignment, financial runway, and short interest positioning — is the approach supported by the academic evidence from Verdad's research. For more on each dimension, see our articles on cash runway and catalyst timing and short interest as a signal. No single indicator is sufficient, but when all four align, the probability distribution shifts meaningfully.